Last update Aug. 20, 2022
It is a calcium channel blocker chemically unrelated to others such as diltiazem, nifedipine or verapamil. It is used in the treatment of angina pectoris. Oral administration.
At latest update no published data were found on excretion into breast milk.
Its high plasma protein-binding capacity makes it unlikely the passage to the breast milk, however, it has a very long elimination time.
It can cause QT prolongation on the EKG and serious cardiac arrhythmias. It has been withdrawn from the market in many countries.
During breastfeeding an alternative drug that is known to be safer is preferred, especially during the neonatal period and in case of a premature infant.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM